Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease
← catalyst calendarSponsored by Akebia Therapeutics (industry) · AKBA — their whole pipeline →.
Phase
Phase 3
Status
Withdrawn
Study type
Interventional
Design
Na · None · Treatment
Enrollment
0actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jan 2025 | estimated | When the study began enrolling |
| Primary completion | Jul 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2021-10-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Anemia of Chronic Kidney Disease
Intervention
- Drug: vadadustat — also filed as AKB-6548
Primary outcome
what the primary-completion date above is the date OFMean Change in Hemoglobin (Hb) Values Between Baseline and the Primary Evaluation Period (Average Hb From Weeks 21 to 28)
measured Baseline; Weeks 21 to 28
Permalink · AKBA's whole pipeline · Catalyst calendar · Every registered study · What changed